Влияние некоторых иммуномодуляторов на иммунную систему и переносимость адъювантной химио-или химиолучевой терапии у больных раком молочной железы
Диссертация
К моменту окончания исследования появились новые лекарственные формы выпуска препарата полиоксидонийсуппозитории по 6 и 12 мг, что может значительно улучшить качество жизни пациенток избавив от необходимости делать внутримышечные инъекции, однако биодоступность данной формы выпуска в комбинации с химиотерапией и выраженность иммуностимулирующего эффекта пока изучены не были. На основании… Читать ещё >
Содержание
- Глава I. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. Общие сведения о р|аке молочной железы
- 1. 2. Тактика лечения больных с минимальной и средней степенью риска развития рецидива
- 1. 3. Тактика лечения пациенток с высокой степенью риска развития рецидива
- 1. 4. Системная химиотерапия: стандарты лечения
- 1. 5. Рольтаксанов
- 1. 6. Новые возможности
- 1. 7. Осложнения химиотерапии
- 1. 7. 1. Медикаментозная миелосупрессия
- 1. 7. 2. Гематопоэтическая функция костного мозга
- 1. 7. 3. Механизмы медикаментозной миелосупрессии
- 1. 7. 4. Влияние цитотоксических агентов на иммунную систему
- 1. 8. Иммуномодуляторы
- 1. 8. 2. Состав ликопида
- 1. 8. 3. Основные свойства ликопида
- 1. 8. 4. Области клинического применения производных мурамилпептидного ряда
- 1. 8. 5. Полиоксидоний
- 1. 8. 6. Детоксицирующие и антиоксидантные свойства ПО
- 1. 8. 7. Клиническое применение полиоксидония
- 2. 1. Исследуемые группы больных
- 2. 2. Методы клинико-лабораторного обследования
- 2. 3. Схемы назначения иммунотропной терапии
- 2. 4. Методы оценки качества жизни пациенток, получающих химиотерапию. Ш
- 2. 5. Экспериментальная часть
- 2. 6. Статистические методы анализа данных
- 3. 1. Общая характеристика групп
- 3. 2. Оценка переносимости и побочных эффектов ликопида, полиоксидония и комбинации ликопида и полиоксидония в процессе адьювантной химиотерапии
- 3. 3. Оценка влияния ликопида, полиоксидония и комбинации ликопида и полиоксидония на переносимость адьювантной химиотерапии
- 3. 4. Исследование влияния иммуномодулятора Полиоксидоний на качество жизни пациенток в процессе химиоили химиолучевой терапии
- 3. 5. Оценка иммунного статуса пациентов в процессе лечения
- 3. 5. 1. Динамика показателей иммунного статуса
- 3. 5. 2. Оценка эффективности иммуномодуляторов по показателям иммунного статуса
Список литературы
- Манько В.М., Скворцов В., Мастернак Т. Б., Иванова А. С. и др. Иммунология 2: 23−26, 1989.
- Манько В.М., Скворцов В., Мастернак Т. Б., Иванова А. С. Иммунология 6: 34−37, 1988.
- Манько В.М., Скворцов В., Мастернак Т. Б., Ларин А. С. и др. Иммунология 1:38−41, 1989.
- Носков Ф.С., Никитина Л. Е., Масленникова Л. К., Фридман Е. А. Иммунология 4: 53−55, 1984.
- Пинегин Б.В., Некрасов А. В., Хаитов P.M. Иммуномодулятор Полиоксидоний: механизмы действия и аспекты клинического применения. 2004. Цитокины и воспаление. Т. 3, № 3, с. 41−47.
- Пинегин Б.В., Ханухова Л. М., Рабинович О. Ф., Андронова Т. М. Новые аспекты клинического применения ликопида при заболеваниях, связанных с нарушением иммунитета. Медицинская Иммунология. 1999,3−4, 127−128.
- Рахмилевич А.Л., Рахимова В. К., Андронова Т. М., Бовин Н. В. Антибиотик, химиотер. 34: 586−588, 1989.
- Степанова Е.Н., Кашкин К. П., Китаева М. Н., Абашев Ю. П. Иммунология 3: 37−40, 1985.
- Уманский В., Тараховский А., Андронова Т. Бюллетень экспериментальной биологии и медицины XCIX: 685−687, 1985.
- Хаитов P.M., Пинегин Б. В. Вторичные имму, но дефициты: клиника, диагностика, лечение. Иммунология, 1999, 14−17.
- Andronova Т., Ivanov. «The structure and Immunological function of glu-cosaminylmuramyl peptides.» Sov. Medical Reviews. D. Immunology (Harwood Academic Publishers) 4: 1−63, 1991.
- Armstrong N.A., Bolton E.J., Morris D.L. Study on the reduction of chemotherapy induced neutropenia in mice using glucosaminylmuramyl dipep-tide. Arzneimittelforschung. 1999 Aug-49(8):716−20.
- Arriagada R., Le M.G., Rochard F., Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996- 14:1558−1564.
- Azuma I. «Review: Inducer of cytokines in vivo: overview of field and romurtide experience.» Int. J. Immunopharmac. 14: 487−496, 1992.
- Bahr G.M., Shaaban M.A., Gabriel M., al-Shimali В., Siddiqui Z., Chugh T.D., Denath F.M., Shahin A., Behbehani K., Chedid L., et al. Improved immunotherapy for pulmonary tuberculosis with Mycobacterium vaccae. Tubercle. 1990 Dec-71(4):259−66.
- Bahr G.M. Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J Antimicrob Chemother. 2003 Jan-51(l):5−8. Review.
- Bailey F.A., Lilly M., Bertoli L.F., et al. An antibody that inhibits in vitro bone marrow proliferation in a patient with systemic lupus erythematosus and aplastic anemia. Arthritis Rheum 31 1989- 31: 901−5.
- Balitsky K.P., Umansky- V.Y., Tarakhovsky A.M., Andronova T.M. et al. «Glucosaminylmuramyl dipeptide induced changes in murine macrophage metabolism.» Int. J.Immunopharmac. 11: 429−434, 1989.
- Balkwill F.R. The colony stimulating factors. In: Balkwill FR, editor. Cytokines in cancer therapy. Oxford: Oxford University Press, 1989: 114.
- Behbehani K., Beller D.I., Unanue E.R. «The effect of beryllium and other adjuvants on la expression by macrophages.» J. Immunol. 134: 2047−2049, 1985.
- Bomford R., Stapleton M., Winsor S., McKnight A. et al. «The control of the antibody isotype response to recombinant human immunodeficiency virus gpl20 antigen by adjuvants.» AIDS Res. Human Retrov. S: 1765−1771, 1992.
- Brenner B.G., Gryllis С., Wainberg M.A. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases 1991- J. Leukoc. Biol. 50: 628−640.
- Campbell M.J., Esserman L., Byars N.E., Allison A.C. et al. «Idiotype vaccination against marine В cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity.» J. Immunol. 145: 1029−1036, 1990.
- Cella D.F., Bonomi A.E. Measuring quality of life: 1995 update // Oncology. Chicago, 1995.-p.1−14.
- Cella D.F., Tusky D., Gray G. The functional assessment of cancer therapy scale. Development and validation of the general measure // J. Clin. Oncol. 1993. -№ 11.- p.570−579.
- Chabner B.A., Wilson W. Pharmacology and toxicity of antineoplastic drugs. In: Beutler E., Lichtman M.A., Coller B.S., et al., editors. Hematology. New York: McGraw Hill, 1995: 143−55.
- Chan J.K.C., Sin V.C., Wong K.F., et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997−89:4501−4513.
- Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gra-dishar W.J., Davidson N.E., Martino S., Livingston R., Ingle J.N.,
- De Naeyer В., De Meerleer G., Braems S., Vakaet L., Huys J. Collagen vascular diseases and radiation therapy: a critical review. Int J Radiat Oncol Biol Phys 1999- 44:975−980.
- Dexter T.M. Stem cells in normal growth and disease. BMJ 1987- 295: 1192−4.
- Drenou В., Amiot L., Setterblad N., Taque S., Guilloux V., Charron D., Fauchet R, and Mooney N. MHC class II signaling function is regulated during maturation of plasmacytoid dendritic cells. 2005- J. Leukoc. Biol., v. 77(4): 560−567.
- Early Breast Cancer Trialists Group. Polychemotherapy for early breast cancer- an overview of the randomised trials. Lancet 1998- 352:930−942.
- Early Breast Cancer Trialists' Collaborative Group. 5th Annual Meeting of the Early Breast Cancer Trialists' Collaborative Group, Oxford, UK, 21−22 September, 2000.
- Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. N Engl J Med 1988−319:1681−1692.
- Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992−339:71−85.
- Erslev A.J., Lichtman M.A. Structure and function of the marrow. In: Williams W.J., Beutler E., Erslev A.J., et al., editors. Hematology. New York: McGraw Hill, 1990: 37−47.
- Ferlay J., Bray F., Pisani P., Parkin D.M. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide, versionl.0. IARC CancerBase No. 5. Lyon: IARC Press, 2001.
- Ferlay J., Bray F., Sankila R., Parkin D.M. EUCAN: cancer incidence, mortality and prevalence in the European Union 1998, version 5.0. IARC CancerBase No. 4. Lyon: IARC Press, 1999.
- Fisher В., Redmond C. Lumpectomy for breast cancer: an update of the NSABP experience. National surgical adjuvant breast and bowel project. J Natl Cancer Inst Monogr 1992−11:7−13.
- Fitchen J. J., Cline M.J., Saxon A., et al. Serum inhibitors of hemopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: recovery after exchange plasmapheresis. Am J Med 1979- 66: 537−42.
- Gianan M.A., Kleinerman E.S. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm. 1998 Oct- 13(5):363−8.
- Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann В., Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003- 21:33 573 365.
- Hartwell L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992- 71:543−6.
- Ishihara C., Yamamoto K., Hamada H. et al. «Effect of steriyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance on Cornybacte-rium kutsoheri infection in cortisone-treated mice.» Vaccine 2: 261−264, 1984.
- Ishihara C., Hamada H., Yamamoto K. et al. «Effect of muramyl dipeptide and its stearoyl derivates on resistance to Sendai virus infection in mice.» Vaccine 3: 370−374, 1985.
- Jaber B.L., Perianayagam M.C., Balakrishnan V.S., King A.J., Pereira B. Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system. 2001. J. Leukoc. Biol. 69: 1006−1012.
- Janeway C.A., Travers P., Walport M., Shlomchik M.J. Immunobiology 6th edition.
- Kleinerman E.S., Gano J.B., Johnston D.A., Benjamin R.S., Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995 Apr-18(2):93−9.
- Kotnik V., Stale A. Potential therapeutic indications for synthetic desmu-ramyl MDP analogue (LK-409). Pflugers Arch. 1996- 431 (6 Suppl 2): R235−6.
- Kurtz J.M., Jacquemier J., Amalric R., Brandone H., Ayme Y., Hans D., Bressac C., Spitalier J.M. Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 1990- 212:38−44.
- Maciejewski J.P., Selleri C., Sato Т., et al. A severe and consistent deficit in marrow and circulating primitive haemopoietic cells (long term culture initiating cells) in acquired aplastic anemia. Blood 1998- 91: 1983−91.
- Math’e G., Amiel J.L., Schwarzenberg L., et al. Bone marrow graft in man after conditioning by antilymphocytic serum. BMJ 170−2: 131−6.
- Matsumoto K., Ogawa H., Kusama T. et al. «Stimulation of non specific resistance to infection induced by 6-O-acylmuramyl dipeptide in mice.» Infect. Immun. 32: 748−758, 1981.
- Mehta K., Shahid U., Malavasi F. (1996) Human CD38, a cell-surface protein with multiple functions FASEB J 10,1408−1417.
- Mosmann T.R., Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol. Today, 1996, 17, 138−146.
- Nakajima R., Ishida V., Yamaguchi F. et al. «Beneficial effect of murocta-sin on experimental leukopenia induced by cyclophosphamide or irradiation in mice.» Arzneim. Forsch. / Drug Res. 38: 986−992, 1988.
- Nesmeyanov V., Golovina Т., Valyakina Т., Andronova T.M. «Cellular and molecular mechanisms of biological activity of muramyl peptides.» In: «Immunotherapy of Infections.» (Ed. N. Masihi) (New York, Basel, Hong Kong: Marcel Dekker, Inc.) 213 223, 1994.
- Nesmeyanov V.A., Khaidukov S.V., Komaleva R.L., Andronova T.M. et al. «Muramylpeptides augment expression of la-antigens on mouse macrophages.» Biomed. Sci. 1: 151−154, 1990.
- Noroski L.M., Shearer W.T. Screening for primary immunodeficiencies in clinical immunology laboratory. Clin.Immunol.Immunopath. 1998, 86, 237−245
- Oppenheim J.J., Tagawa A., Chedid L., Mizel S. «Components of mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating fatcor.» Cell. Imunol.59: 71−81, 1980.
- Pasquier В., Lepelletier Y., Baude C., Hermine O., and Monteiro R. C. Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells. 2004- Journal of Leukocyte Biology. 76: p. 1134−1141.
- Pritchard K.I., Levine M.N., Bramwell V.H.C., Shepherd L.E., Tu D., Paul N. A randomized trial comparing CEF to CMF in premenopausal women with node positive breast cancer: update of NCIC CTG MA. 5. Breast Cancer Res Treat 2002 abstract 17.
- Rawlins M.D., Thompson J.W. Pathogenesis of adverse drug reactions. In: Davis DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 44.
- Rodenhuis S., Bontenbal M., Beex L.V., et al. Netherlands Working Party on Autologous Transplantation in Solid Tumors: high-dose chemotherapywith hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003−349:7−16.
- Romet-Lemonne J.L., Mills В., Fridman W.H., Munsell M. Prospectively planned analysis of data from a phase III study of liposomal muramyl-tripeptide phosphatidylethanolamine in the treatment of osteosarcoma. J Clin Oncol. 2005 Sep 10−23(26):6437−8.
- Ross J.S., Fletcher J.A. The HER/2neu oncogene: prognostic factor, predictive factor, and target for therapy. Semin Cancer Biol 1999- 9:125−138.
- Shimoda K., Okamura S., Harada N. et al. «Production of interleukin-6 from macrophages by MDP-Lys (18)6 romurtide.» Res. Commun. Chem. Path. Pharmac. 70: 289−296, 1990.
- Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987- 235:177 182.
- Spyratos F., Bouchet C., Tozlu S., Labroquere M., Vignaud S., Becette V., Lidereau R., Bieche I. Prognostic value of uPA, PAI-1 and PAI-2 mRNA expression in primary breast cancer. Anticancer Res 2002- 22:2997−3003.
- Truong M.J., Delsart V., Bahr G.M. Differentially expressed genes in HIV-1-infected macrophages following treatment with the virus-suppressive immunomodulator murabutide. Virus Res. 2004 Jan-99(l):25−33.
- Tsubura E., Nomura Т., H. Nitani et al. «Restorative activity of muroctasin on leukopenia associated with anticancer treatment.» Arzneim. Forsch. / Drug Res. 38: 983−986, 1988.
- Van 't Veer L.J., De Jong D. The microarray way to tailored cancer treatment. Nat Med 2002- 8:13−14.
- Veronesi U., Banfi A., Salvadori В., et al. Breast conservation is the treatment of choice in small breast cancer: Long-term results of a randomized trial. Eur J Cancer 1990- 26:668−670.
- Walker S., Rosser R. Quality of life assessment: issues in the 1990s. Klu-wer Academic Publ., 1993.
- Witthaut R., Farhood A., Smith C. W., and Jaeschke H. Complement and tumor necrosis factor-alpha contribute to Mac-1 (CD1 lb/CD 18) up-regulation and systemic neutrophil activation during endotoxemia in vivo. 1994. J. Leukoc. Biol. 55: 105−111.
- Yamaguchi F., Akahane K., Takashi Т., Tsukada W. «Production of colony-stimulating factor from macrophages by muroctasin.» Arzneim. Forsch. / Drug Res. 38: 983−986, 1988.
- Yanagawa H., Haku Т., Takeuchi E., Suzuki Y., Nokihara H., Sone S. Intrapleural therapy with MDP-Lys (LI8), a synthetic derivative of muramyl dipeptide, against malignant pleurisy associated with lung cancer. Lung Cancer. 2000 Feb-27(2):67−73.
- Young N.S., Barrett A.J. The treatment of severe acquired aplastic anemia. Blood 1995- 85: 3367−77.
- Young N.S., Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997- 336: 1365−72.
- Непараметрический критерий Краскела-Уоллиса.
- Статистический анализ проведен с помощью программы STATISTICA 6.0.1. ФАЗА 0
- Depend.: Multiple Comparisons р values (2-tailed) — лeйкoц.(fedenko-data)лейкоц. Kruskal-Wallis test: H (3, N= 89) =2,740 264 p =, 4334 1 2 3 4
- R:41,121 R:45,167 R:43,554 R:53,8531 1,000 1,000 0,6402 1,000 1,000 1,0003 1,000 1,000 1,0004 0,640 1,000 1,000
- Depend.: Multiple Comparisons p values (2-tailed) — лимф, (fedenko-data)лимф. Kruskal-Wallis test: H (3, N= 85) =10,62 078 p = 0140 1 2 3 4
- R:35,500 R: 52,300 R:37,180 R:55,7061 0,200 364 1 0,465 232 0,200 364 0,364 158 13 1 0,364 158 0,1 017 244 0,46 523 1 0,101 724
- Depend.: Multiple Comparisons p values (2-tailed) — лимф.абс. (fedenko-data)лимф.абс. Kruskal-Wallis test: H (3, N= 85) =20,94 745 p = 0001 1 2 3 4
- R:32,786 R:52,767 R:34,980 R:63,0001 0,68 417 1 0,4 112 0,68 417 0,164 077 13 1 0,164 077 0,18 284 0,411 1 0,1 828
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 (fedenko-data)
- CD3 Kruskal-Wallis test: H (3, N= 96) =1,997 931 p =, 57 281 2 3 4
- R:47,516 R:47,533 R:45,161 R:56,3161 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 abs. (fedenko-data)
- CD3 abs. Kiuskal-Wallis test: H (3, N= 84) =18,68 660 p = 31 2 3 4
- R:32,786 R:51,400 R:35,560 R:62,0001 0,10 249 1 0,7 952 0,10 249 0,28 067 13 1 0,28 067 0,42 614 0,795 1 0,4 261
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 (fedenko-data)
- CD4 Kiuskal-Wallis test: H (3, N= 97) =2,919 765 p =, 40 421 2 3 4
- R:48,661 R:45,100 R:45,339 R:58,1251 1 1 12 1 1 13 1 1 0,6 792 034 1 1 0,679 203
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 abs. (fedenko-data)
- CD4 abs. Kiuskal-Wallis test: H (3, N= 85) =18,63 653 p =, 31 2 3 4
- R:34,357 R:48,733 R:35,200 R:63,6471 0,412 191 1 0,6 812 0,412 191 0,55 904 0,5 283 373 1 0,55 904 0,14 764 0,681 0,528 337 0,1 476
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 (fedenko-data)
- CD8 Kruskal-Wallis test: H (3, N= 97) = 6 061 841 p =, 89 501 2 3 4
- R:46,661 R:53,067 R:48,355 R:50,5751 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 abs. (fedenko-data)
- CD8 abs. Kruskal-Wallis test: H (3, N= 85) =13,58 266 p =, 351 2 3 4
- R:35,393 R:53,800 R:35,360 R:57,2351 0,118 577 1 0,239 922 0,118 577 0,132 968 13 1 0,132 968 0,288 694 0,23 992 1 0,28 869
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 (fedenko-data)
- CD20 Kruskal-Wallis test: H (3, N= 97) =2,661 973 p =, 44 671 2 3 4
- R:45,306 R:59,133 R:47,048 R:50,1501 0,709 817 1 12 0,709 817 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 abs. (fedenko-data)
- CD20 abs. Kruskal-Wallis test: H (3, N= 85) =12,75 635 p =, 521 2 3 4
- R:33,893 R:54,933 R:37,640 R:55,3531 0,46 294 1 0,281 152 0,46 294 0,191 554 13 1 0,191 554 0,1 346 074 0,28 115 1 0,134 607
- Depend.: Multiple Comparisons p values (2-tailed) — HLA-DR (fedenko-data)
- HLA-DR Kruskal-Wallis test: H (3, N= 97) =12,73 039 p =, 531 2 3 4
- R:52,016 R:69,367 R:38,774 R:44,9001 0,299 987 0,383 905 12 0,299 987 0,3 291 0,655 613 0,383 905 0,3 291 14 1 0,65 561 1
- Depend.: Multiple Comparisons p values (2-tailed) — HLADR abs. (fedenko-data)
- HLADR abs. Kruskal-Wallis test: H (3, N= 85) =19,57 210 p =, 21 2 3 4
- R:36,714 R:63,133 R:31,600 R:52,3531 0,4 931 1 0,2 359 532 0,4 931 0,549 13 1 0,549 0,448 724 0,235 953 1 0,44 872
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 (fedenko-data)
- CD38 Kruskal-Wallis test: H (3, N= 97) =10,95 208 p =, 1 201 2 3 4
- R:50,355 R: 61,633 R:36,371 R:57,0001 1 0,30 274 12 1 0,25 925 13 0,30 274 0,25 925 0,636 154 1 1 0,63 615
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 abs. (fedenko-data)
- CD38 abs. Kruskal-Wallis test: H (3, N= 85) =22,79 398 p =, 1 2 3 4
- R:3 7,321 R:57,600 R:29,040 R:60,0001 0,61 409 1 0,168 242 0,61 409 0,2 373 13 1 0,2 373 0,3 964 0,16 824 1 0,396
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 (fedenko-data)
- CD25 Kruskal-Wallis test: H (3, N= 97) =18,72 728 p =, 31 2 3 4
- R:63,613 R:28,000 R:50,194 R:40,2501 0,345 0,36 302 0,228 072 0,345 0,73 042 13 0,36 302 0,73 042 14 0,22 807 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 abs. (fedenko-data)
- CD25 abs. Kruskal-Wallis test: H (3, N= 85) =9,986 826 p =, 1 871 2 3 4
- R:51,786 R:27,067 R:41,480 R:44,8241 0,10 486 0,774 883 12 0,10 486 0,442 598 0,2 535 773 0,774 883 0,442 598 14 1 0,253 577 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 (fedenko-data)
- CD16 Kruskal-Wallis test: H (3, N= 97) =1,886 306 p =, 59 631 2 3 4
- R:49,935 R:54,433 R:49,984 R:41,9501 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 abs. (fedenko-data)
- CD16 abs. Kruskal-Wallis test: H (3, N= 85) =5,961 468 p =, 11 351 2 3 4
- R:38,357 R:52,667 R:37,520 R:50,1761 0,419 958 1 0,7 161 422 0,419 958 0,361 439 13 1 0,361 439 0,6 170 554 0,716 142 1 0,617 055
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb (fedenko-data)
- CDllb Kruskal-Wallis test: H (3, N= 95) =2,124 286 p =, 54 701 2 3 4
- R:48,117 R:48,200 R:43,233 R:54,8251 1 1 12 1 1 13 1 1 0,871 424 1 1 0,87 142
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb abs. (fedenko-data)
- CDllb abs. Kruskal-Wallis test: H (3, N= 83) =13,53 236 p =, 361 2 3 4
- R: 35,963 R:49,067 R:33,167 R:57,8241 0,548 304 1 0,203 882 0,548 304 0,270 331 13 1 0,270 331 0,75 084 0,20 388 1 0,7 508
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 (fedenko-data)
- CD50 Kruskal-Wallis test: H (3, N= 96) =4,688 634 p =, 19 611 2 3 4
- R:52,350 R:36,767 R:53,339 R:44,0251 0,461 356 1 12 0,461 356 0,351 393 13 1 0,351 393 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 abs. (fedenko-data)
- CD50 abs. Kruskal-Wallis test: H (3, N= 84) =18,17 339 p =, 41 2 3 4
- R:33,667 R:50,867 R:34,280 R:61,2351 0,171 302 1 0,15 712 0,171 302 0,22 404 13 1 0,22 404 0,26 364 0,1 571 1 0,2 636
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA (fedenko-data)
- CD45RA Kruskal-Wallis test: H (3, N= 96) =3,7 492 p =, 39 051 2 3 4
- R:46,617 R:43,833 R:46,500 R:57,9251 1 1 0,9 579 232 1 1 0,8 316 233 1 1 0,9 163 024 0,957 923 0,831 623 0,916 302
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA abs. (fedenko-data)
- CD45RA abs. Kruskal-Wallis test: H (3, N= 84) =15,5 612 p = 181 2 3 4
- R:35,259 R:46,333 R:35,240 R:61,2941 0,951 625 1 0,33 982 0,951 625 0,982 661 0,500 313 1 0,982 661 0,40 774 0,3 398 0,50 031 0,4 077
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 (fedenko-data)
- CD5 Kruskal-Wallis test: H (3, N= 96) =5,305 164 p =15 081 2 3 4
- R:48,433 R:52,200 R:40,468 R:58,2751 1 1 12 1 1 13 1 1 0,1 549 514 1 1 0,154 951
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 abs. (fedenko-data)
- CD5 abs. Kruskal-Wallis test: H (3, N= 84) =21,9 759 p =, 11 2 3 4
- R:32,296 R:52,133 R:34,280 R:62,2941 0,6 935 1 0,4 282 0,6 935 0,150 147 13 1 0,150 147 0,15 534 0,428 1 0,1 553
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 (fedenko-data)
- CD7 Kruskal-Wallis test: H (3, N= 96) =12,14 362 p = 691 2 3 4
- R:45,367 R:45,533 R:40,774 R:67,4001 1 1 0,368 712 1 1 0,129 323 1 1 0,51 624 0,36 871 0,12 932 0,5 162
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 abs. (fedenko-data)
- CD7 abs. Kruskal-Wallis test: H (3, N= 84) =20,99 972 p =, 11 2 3 4
- R:33,704 R:48,467 R:33,720 R:64,l 181 0,361 144 1 0,3 392 0,361 144 0,384 964 0,4 206 143 1 0,384 964 0,4 424 0,339 0,420 614 0,442
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 (fedenko-data)
- CD71 Kruskal-Wallis test: H (3, N= 96) =4,668 783 p =19 771 2 3 4
- R:54,950 R:36,033 R:49,081 R:47,2751 0,190 567 1 12 0,190 567 0,818 691 13 1 0,818 691 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 abs. (fedenko-data)
- CD71 abs. Kruskal-Wallis test: H (3, N= 84) =4,486 633 p =, 21 351 2 3 4
- R:42,704 R:35,533 R:39,600 R:52,5881 1 1 12 1 1 0,2 904 813 1 1 0,5 418 234 1 0,290 481 0,541 823
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 (fedenko-data)
- CD95 Kruskal-Wallis test: H (3, N= 96) =11,9 643 p =, 1 121 2 3 4
- R:42,583 R:53,367 R:41,145 R:65,1251 1 1 0,303 642 1 0,978 286 13 1 0,978 286 0,161 244 0,30 364 1 0,16 124
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 abs. (fedenko-data)
- CD95 abs. Kruskal-Wallis test: H (3, N= 84) =23,86 963 p =, 1 2 3 4
- R:33,481 R:50,533 R:32,280 R:64,7651 0,179 687 1 0,2 062 0,179 687 0,131 699 0,5 973 963 1 0,131 699 0,1 364 0,206 0,597 396 0,136
- Depend.: Multiple Comparisons p values (2-tailed) — CD4/CD8 (fedenko-data)
- CD4/CD8 Kruskal-Wallis test: H (3, N= 97) =1,2 594 p =, 80 061 2 3 4
- R:50,081 R:44,533 R:47,306 R:53,3001 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG МЕ/мл (fedenko-data)
- G МЕ/мл Kruskal-Wallis test: H (3, N= 94) =3,814 704 p =, 28 221 2 3 4
- R:46,482 R:41,267 R:54,823 R:42,2501 1 1 12 1 0,68 472 13 1 0,68 472 0,6 484 034 1 1 0,648 403
- Depend.: Multiple Comparisons p values (2-tailed) — IgA МЕ/мл (fedenko-data)
- A МЕ/мл Kruskal-Wallis test: H (3, N= 94) =6,875 348 p =, 7 601 2 3 4
- R:52,732 R:33,833 R:52,968 R:41,9501 0,182 253 1 12 0,182 253 0,154 438 13 1 0,154 438 0,9 544 094 1 1 0,954 409
- Depend.: Multiple Comparisons p values (2-tailed) — IgM МЕ/мл (fedenko-data)
- M МЕ/мл Kruskal-Wallis test: H (3, N= 93) =2,59 028 p =, 56 021 2 3 4
- R:47,389 R:53,067 R:41,952 R:49,7501 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG г/л (fedenko-data)
- G г/л Kruskal-Wallis test: H (3, N= 94) =5,334 721 p =, 14 891 2 3 4
- R:45,429 R:40,567 R:56,419 R:41,7751 1 0,733 567 12 1 0,387 934 13 0,733 567 0,387 934 0,3 674 544 1 1 0,367 454
- Depend.: Multiple Comparisons p values (2-tailed) — IgA г/л (fedenko-data)
- A г/л Kruskal-Wallis test: H (3, N= 94) =7,229 730 p =, 6 491 2 3 4
- R:52,304 R:33,567 R:53,613 R:41,7501 0,190 946 1 12 0,190 946 0,116 826 13 1 0,116 826 0,7 767 594 1 1 0,776 759
- Depend.: Multiple Comparisons p values (2-tailed) — IgM г/л (fedenko-data)
- M г/л Kruskal-Wallis test: H (3, N= 93) =2,59 028 p =, 56 021 2 3 4
- R:47,389 R:53,067 R:41,952 R:49,7501 1 1 12 1 1 13 1 1 14 1 1 1
- Непараметрический критерий Краскела-Уоллиса.
- Статистический анализ проведен с помощью программы STATISTICA 6.0.1. ФАЗА 1
- Depend.: Multiple Comparisons р values (2-tailed) — лейкоц. (fedenko-data)лейкоц. Kruskal-Wallis test: H (3, N= 89) =2,740 264 p =, 4334 1 2 3 4
- R:41,121 R:45,167 R:43,554 R:53,8531 1,000 1,000 0,6402 1,000 1,000 1,0003 1,000 1,000 1,0004 0,640 1,000 1,000
- Depend.: Multiple Comparisons p values (2-tailed) — лимф, (fedenko-data)лимф. Kruskal-Wallis test: H (3, N= 85) =10,62 078 p =, 0140 1 2 3 4
- R:35,500 R:52,300 R:37,180 R: 55,7061 0,200 364 1 0,465 232 0,200 364 0,364 158 13 1 0,364 158 0,1 017 244 0,46 523 1 0,101 724
- Depend.: Multiple Comparisons p values (2-tailed) — лимф.абс. (fedenko-data)лимф.абс. Kruskal-Wallis test: H (3, N= 85) =20,94 745 p =, 0001 1 2 3 4
- R:32,786 R: 52,767 R: 34,980 R:63,0001 0,68 417 1 0,4 112 0,68 417 0,164 077 13 1 0,164 077 0,18 284 0,411 1 0,1 828
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 (fedenko-data)
- CD3 Kruskal-Wallis test: H (3, N= 96) =1,997 931 p =, 57 281 2 3 4
- R:47,516 R:47,533 R:45,161 R:56,3161 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 abs. (fedenko-data)
- CD3 abs. Kruskal-Wallis test: H (3, N= 84) =18,68 660 p =, 31 2 3 4
- R:32,786 R:51,400 R:35,560 R:62,0001 0,10 249 1 0,7 952 0,10 249 0,28 067 13 1 0,28 067 0,42 614 0,795 1 0,4 261
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 (fedenko-data)
- CD4 Kruskal-Wallis test: H (3, N= 97) =2,919 765 p =, 40 421 2 3 4
- R:48,661 R:45,100 R:45,339 R:58,1251 1 1 12 1 1 13 1 1 0,6 792 034 1 1 0,679 203
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 abs. (fedenko-data)
- CD4 abs. Kruskal-Wallis test: H (3, N= 85) =18,63 653 p =, 31 2 3 4
- R:34,357 R:48,733 R:35,200 R:63,6471 0,412 191 1 0,6 812 0,412 191 0,55 904 0,5 283 373 1 0,55 904 0,14 764 0,681 0,528 337 0,1 476
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 (fedenko-data)
- CD8 Kruskal-Wallis test: H (3, N= 97) = 6 061 841 p =, 89 501 2 3 4
- R:46,661 R: 53,067 R:48,355 R:50,5751 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 abs. (fedenko-data)
- CD8 abs. Kruskal-Wallis test: H (3, N= 85) =13,58 266 p =, 351 2 3 4
- R:35,393 R:53,800 R:35,360 R:57,2351 0,118 577 1 0,239 922 0,118 577 0,132 968 13 1 0,132 968 0,288 694 0,23 992 1 0,28 869
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 (fedenko-data)
- CD20 Kruskal-Wallis test: H (3, N= 97) =2,661 973 p =, 44 671 2 3 4
- R:45,306 R:59,133 R:47,048 R:50,1501 0,709 817 1 12 0,709 817 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 abs. (fedenko-data)
- CD20 abs. Kruskal-Wallis test: H (3, N= 85) =12,75 635 p =, 521 2 3 4
- R:33,893 R:54,933 R:37,640 R:55,3531 0,46 294 1 0,281 152 0,46 294 0,191 554 13 1 0,191 554 0,1 346 074 0,28 115 1 0,134 607
- Depend.: Multiple Comparisons p values (2-tailed) — HLA-DR (fedenko-data)
- HLA-DR Kruskal-Wallis test: H (3, N= 97) =12,73 039 p =, 531 2 3 4
- R:52,016 R:69,367 R:38,774 R:44,9001 0,299 987 0,383 905 12 0,299 987 0,3 291 0,655 613 0,383 905 0,3 291 14 1 0,65 561 1
- Depend.: Multiple Comparisons p values (2-tailed) — HLADR abs. (fedenko-data)
- HLADR abs. Kruskal-Wallis test: H (3, N= 85) =19,57 210 p =, 21 2 3 4
- R:36,714 R:63,133 R:31,600 R:52,3531 0,4 931 1 0,2 359 532 0,4 931 0,549 13 1 0,549 0,448 724 0,235 953 1 0,44 872
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 (fedenko-data)
- CD38 Kruskal-Wallis test: H (3, N= 97) =10,95 208 p =, 1 201 2 3 4
- R: 50,3 5 5 R:61,633 R:36,371 R:57,0001 1 0,30 274 12 1 0,25 925 13 0,30 274 0,25 925 0,636 154 1 1 0,63 615
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 abs. (fedenko-data)
- CD38 abs. Kruskal-Wallis test: H (3, N= 85) =22,79 398 p =, 1 2 3 4
- R:37,321 R:57,600 R:29,040 R:60,0001 0,61 409 1 0,168 242 0,61 409 0,2 373 13 1 0,2 373 0,3 964 0,16 824 1 0,396
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 (fedenko-data)
- CD25 Kruskal-Wallis test: H (3, N= 97) =18,72 728 p =, 31 2 3 4
- R:63,613 R:28,000 R:50,194 R:40,2501 0,345 0,36 302 0,228 072 0,345 0,73 042 13 0,36 302 0,73 042 14 0,22 807 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 abs. (fedenko-data)
- CD25 abs. Kruskal-Wallis test: H (3, N= 85) =9,986 826 p =, 1 871 2 3 4
- R:51,786 R:27,067 R:41,480 R:44,8241 0,10 486 0,774 883 12 0,10 486 0,442 598 0,2 535 773 0,774 883 0,442 598 14 1 0,253 577 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 (fedenko-data)
- CD16 Kruskal-Wallis test: H (3, N= 97) =1,886 306 p =, 59 631 2 3 4
- R:49,935 R:54,433 R:49,984 R:41,9501 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 abs. (fedenko-data)
- CD 16 abs. Kruskal-Wallis test: H (3, N= 85) =5,961 468 p = 11 351 2 3 4
- R:38,357 R:52,667 R:37,520 R:50,1761 0,419 958 1 0,7 161 422 0,419 958 0,361 439 13 1 0,361 439 0,6 170 554 0,716 142 1 0,617 055
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb (fedenko-data)
- CDllb Kruskal-Wallis test: H (3, N= 95) =2,124 286 p = 54 701 2 3 4
- R:48,l 17 R:48,200 R:43,233 R:54,8251 1 1 12 1 1 13 1 1 0,871 424 1 1 0,87 142
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb abs. (fedenko-data)
- CDllb abs. Kruskal-Wallis test: H (3, N= 83) =13,53 236 p =, 361 2 3 4
- R:35,963 R:49,067 R:33,167 R:57,8241 0,548 304 1 0,203 882 0,548 304 0,270 331 13 1 0,270 331 0,75 084 0,20 388 1 0,7 508
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 (fedenko-data)
- CD50 Kruskal-Wallis test: H (3, N= 96) =4,688 634 p =, 19 611 2 3 4
- R:52,350 R:36,767 R:53,339 R:44,0251 0,461 356 1 12 0,461 356 0,351 393 13 1 0,351 393 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 abs. (fedenko-data)
- CD50 abs. Kruskal-Wallis test: H (3, N= 84) =18,17 339 p =, 41 2 3 4
- R:33,667 R:50,867 R:34,280 R:61,2351 0,171 302 1 0,15 712 0,171 302 0,22 404 13 1 0,22 404 0,26 364 0,1 571 1 0,2 636
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA (fedenko-data)
- CD45RA Kruskal-Wallis test: H (3, N= 96) =3,7 492 p = 39 051 2 3 4
- R:46,617 R:43,833 R:46,500 R:57,9251 1 1 0,9 579 232 1 1 0,8 316 233 1 1 0,9 163 024 0,957 923 0,831 623 0,916 302
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA abs. (fedenko-data)
- CD45RA abs. Kruskal-Wallis test: H (3, N= 84) =15,5 612 p =, 181 2 3 4
- R:35,259 R:46,333 R:3 5,240 R:61,2941 0,951 625 1 0,33 982 0,951 625 0,982 661 0,500 313 1 0,982 661 0,40 774 0,3 398 0,50 031 0,4 077
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 (fedenko-data)
- CD 5 Kruskal-Wallis test: H (3, N= 96) =5,305 164 p =, 15 081 2 3 4
- R:48,433 R:52,200 R:40,468 R:58,2751 1 1 12 1 1 13 1 1 0,1 549 514 1 1 0,154 951
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 abs. (fedenko-data)
- CD5 abs. Kruskal-Wallis test: H (3, N= 84) =21,9 759 p =, 11 2 3 4
- R:32,296 R:52,133 R:34,280 R:62,2941 0,6 935 1 0,4 282 0,6 935 0,150 147 13 1 0,150 147 0,15 534 0,428 1 0,1 553
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 (fedenko-data)
- CD7 Kruskal-Wallis test: H (3, N= 96) =12,14 362 p =, 691 2 3 4
- R:45,367 R:45,533 R:40,774 R:67,4001 1 1 0,368 712 1 1 0,129 323 1 1 0,51 624 0,36 871 0,12 932 0,5 162
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 abs. (fedenko-data)
- CD7 abs. Kruskal-Wallis test: H (3, N= 84) =20,99 972 p =, 11 2 3 4
- R:33,704 R:48,467 R:33,720 R:64,1181 0,361 144 1 0,3 392 0,361 144 0,384 964 0,4 206 143 1 0,384 964 0,4 424 0,339 0,420 614 0,442
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 (fedenko-data)
- CD71 Kruskal-Wallis test: H (3, N= 96) =4,668 783 p =, 19 771 2 3 4
- R:54,950 R:36,033 R:49,081 R:47,2751 0,190 567 1 12 0,190 567 0,818 691 13 1 0,818 691 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 abs. (fedenko-data)
- CD71 abs. Kruskal-Wallis test: H (3, N= 84) =4,486 633 p =, 21 351 2 3 4
- R:42,704 R:35,533 R:39,600 R:52,5881 1 1 12 1 1 0,2 904 813 1 1 0,5 418 234 1 0,290 481 0,541 823
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 (fedenko-data)
- CD95 Kruskal-Wallis test: H (3, N= 96) =11,9 643 p = 1 121 2 3 4
- R:42,583 R:53,367 R:41,145 R:65,1251 1 1 0,303 642 1 0,978 286 13 1 0,978 286 0,161 244 0,30 364 1 0,16 124
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 abs. (fedenko-data)
- CD95 abs. Kruskal-Wallis test: H (3, N= 84) =23,86 963 p =, 1 2 3 4
- R:33,481 R:50,533 R:32,280 R:64,7651 0,179 687 1 0,2 062 0,179 687 0,131 699 0,5 973 963 1 0,131 699 0,1 364 0,206 0,597 396 0,136
- Depend.: Multiple Comparisons p values (2-tailed) — CD4/CD8 (fedenko-data)
- CD4/CD8 Kruskal-Wallis test: H (3, N= 97) =1,2 594 p =, 80 061 2 3 4
- R:50,081 R:44,533 R:47,306 R:53,3001 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG МЕ/мл (fedenko-data)
- G МЕ/мл Kruskal-Wallis test: H (3, N= 94) =3,814 704 p = 28 221 2 3 4
- R:46,482 R:41,267 R:54,823 R:42,2501 1 1 12 1 0,68 472 13 1 0,68 472 0,6 484 034 1 1 0,648 403
- Depend.: Multiple Comparisons p values (2-tailed) — IgA МЕ/мл (fedenko-data)
- A МЕ/мл Kruskal-Wallis test: H (3, N= 94) =6,875 348 p =, 7 601 2 3 4
- R:52,732 R:33,833 R:52,968 R:41,9501 0,182 253 1 12 0,182 253 0,154 438 13 1 0,154 438 0,9 544 094 1 1 0,954 409
- Depend.: Multiple Comparisons p values (2-tailed) — IgM МЕ/мл (fedenko-data)
- M МЕ/мл Kruskal-Wallis test: H (3, N= 93) =2,59 028 p = 56 021 2 3 4
- R:47,389 R:53,067 R:41,952 R:49,7501 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG г/л (fedenko-data)
- G г/л Kruskal-Wallis test: H (3, N= 94) =5,334 721 p =, 14 891 2 3 4
- R:45,429 R:40,567 R:56,419 R:41,7751 1 0,733 567 12 1 0,387 934 13 0,733 567 0,387 934 0,3 674 544 1 1 0,367 454
- Depend.: Multiple Comparisons p values (2-tailed) — IgA г/л (fedenko-data)
- A г/л Kruskal-Wallis test: H (3, N= 94) =7,229 730 p = 6 491 2 3 4
- R:52,304 R:33,567 R:53,613 R:41,7501 0,190 946 1 12 0,190 946 0,116 826 13 1 0,116 826 0,7 767 594 1 1 0,776 759
- Depend.: Multiple Comparisons p values (2-tailed) — IgM г/л (fedenko-data)
- M г/л Kruskal-Wallis test: H (3, N= 93) =2,59 028 p = 56 021 2 3 4
- R:47,389 R:53,067 R:41,952 R:49,7501 1 1 12 1 1 13 1 1 14 1 1 1
- Непараметрический критерий Краскела-Уоллиса.
- Статистический анализ проведен с помощью программы STATISTICA 6.0.1. ФАЗА 2
- Depend.: Multiple Comparisons р values (2-tailed) — лейкоц. (fedenko-data)лейкоц. Kruskal-Wallis test: H (3, N= 90) =4,571 969 p =, 2060 1 2 3 4
- R:38,125 R:47,100 R:46,183 R:55,0291 1 1 0,2 120 172 1 1 13 1 1 14 0,212 017 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — лимф, (fedenko-data)лимф. Kruskal-Wallis test: H (3, N= 89) =21,31 280 p =, 0001 1 2 3 4
- R:38,648 R:56,767 R:33,350 R:65,2651 0,176 566 1 0,52 592 0,176 566 0,2 493 13 1 0,2 493 0,2 834 0,5 259 1 0,283
- Depend.: Multiple Comparisons p values (2-tailed) — лимф.абс. (fedenko-data)лимф.абс. Kruskal-Wallis test: H (3, N= 89) =25,14 494 p =, 0000 1 2 3 4
- R:36,130 R:55,200 R:34,350 R:68,8821 0,131 394 1 0,2 542 0,131 394 0,64 264 0,8 095 463 1 0,64 264 0,644 0,254 0,809 546 0,64
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 (fedenko-data)
- CD3 Kruskal-Wallis test: H (3, N= 96) =6,87 846 p =10 741 2 3 4
- R:50,081 R:40,500 R:43,290 R:60,7371 1 1 12 1 1 0,2 126 533 1 1 0,1 895 384 1 0,212 653 0,189 538
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 abs. (fedenko-data)
- CD3 abs. Kruskal-Wallis test: H (3, N= 89) =26,7 461 p =, 1 2 3 4
- R:37,259 R:50,667 R:34,200 R:71,3531 0,642 465 1 0,1 212 0,642 465 0,263 122 0,1 428 443 1 0,263 122 0,134 0,121 0,142 844 0,13
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 (fedenko-data)
- CD4 Kruskal-Wallis test: H (3, N= 96) =2,172 887 p =, 53 731 2 3 4
- R:48,839 R:41,233 R:47,548 R:55,2371 1 1 12 1 1 0,8 733 153 1 1 14 1 0,873 315 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 abs. (fedenko-data)
- CD4 abs. Kruskal-Wallis test: H (3, N= 89) =23,45 248 p =, 1 2 3 4
- R:37,l 11 R:51,800 R:54,833 R:69,4711 0,036 0,014 0,3 132 0,036 0,226 983 0,3 211 023 0,014 0,226 983 0,64 0,313 0,321 102 0,6
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 (fedenko-data)
- CD8 Kruskal-Wallis test: H (3, N= 96) =7,658 174 p =, 5 361 2 3 4
- R:46,516 R:48,800 R:41,242 R:63,3421 1 1 0,2 289 732 1 1 0,784 123 1 1 0,388 234 0,228 973 0,78 412 0,38 823
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 abs. (fedenko-data)
- CD8 abs. Kruskal-Wallis test: H (3, N= 89) =24,41 897 p =, 1 2 3 4
- R:36,222 R:53,800 R:34,800 R:69,1761 0,20 775 1 0,2 282 0,20 775 0,120 251 0,5 576 683 1 0,120 251 0,74 0,228 0,557 668 0,7
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 (fedenko-data)
- CD20 Kruskal-Wallis test: H (3, N= 96) =18,99 785 p =, 31 2 3 4
- R:38,532 R:67,267 R:60,226 R:63,4471 0,6 238 0,04 0,128 542 0,6 238 0,1 216 13 0,04 0,1 216 0,25 334 0,12 854 1 0,2 533
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 abs. (fedenko-data)
- CD20 abs. Kruskal-Wallis test: H (3, N= 89) =27,1 119 p =, 1 2 3 4
- R:3 5,926 R:60,200 R:33,167 R:66,8821 0,21 167 1 0,6 532 0,21 167 0,5 621 13 1 0,5 621 0,1 034 0,653 1 0,103
- Depend.: Multiple Comparisons p values (2-tailed) — HLA-DR (fedenko-data)
- HLA-DR Kruskal-Wallis test: H (3, N= 96) =9,809 676 p =, 2 031 2 3 4
- R:49,952 R:66,367 R:39,l 13 R:47,3421 0,365 977 0,753 376 12 0,365 977 0,11 203 0,2 880 643 0,753 376 0,11 203 14 1 0,288 064 1
- Depend.: Multiple Comparisons p values (2-tailed) — HLADR abs. (fedenko-data)
- HLADR abs. Kruskal-Wallis test: H (3, N= 89) =27,38 011 p =, 1 2 3 4
- R:40,148 R:63,867 R:29,833 R:62,8241 0,26 167 0,793 921 0,27 522 0,26 167 0,186 13 0,793 921 0,186 0,1 564 0,2 752 1 0,156
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 (fedenko-data)
- CD38 Kruskal-Wallis test: H (3, N= 96) =24,26 387 p =, 1 2 3 4
- R:42,290 R:66,267 R:34,500 R:67,4471 0,37 255 1 0,116 282 0,37 255 0,1 729 13 1 0,1 729 0,2 954 0,11 628 1 0,295
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 abs. (fedenko-data)
- CD38 abs. Kruskal-Wallis test: H (3, N= 89) =39,83 034 p =, 1 2 3 4
- R:37,000 R:62,800 R:28,367 R:71,3531 0,11 573 1 0,1 052 0,11 573 0,15 13 1 0,15 04 0,105 1 0
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 (fedenko-data)
- CD25 Kruskal-Wallis test: H (3, N= 96) =17,32 157 p =, 61 2 3 4
- R:47,339 R:33,000 R:63,952 R:37,4211 0,610 359 0,113 276 12 0,610 359 0,2 469 13 0,113 276 0,2 469 0,6 484 1 1 0,648
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 abs. (fedenko-data)
- CD25 abs. Kruskal-Wallis test: H (3, N= 89) =10,39 044 p = 1 551 2 3 4
- R:41,lll R:35,133 R:57,067 R:38,5881 1 0,119 458 12 1 0,4 357 13 0,119 458 0,4 357 0,1 108 374 1 1 0,110 837
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 (fedenko-data)
- CD16 Kruskal-Wallis test: H (3, N= 96) =2,920 889 p = 40 401 2 3 4
- R:43,081 R:57,667 R:50,081 R:47,5261 0,575 755 1 12 0,575 755 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 abs. (fedenko-data)
- CD 16 abs. Kruskal-Wallis test: H (3, N= 89) =11,65 308 p =, 871 2 3 4
- R:36,148 R:57,933 R:59,833 R:56,7651 0,45 004 0,0389 0,59 742 0,45 004 0,160 394 13 0,0389 0,160 394 0,1 852 174 0,5 974 1 0,185 217
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb (fedenko-data)
- CDllb Kruskal-Wallis test: H (3, N= 96) =10,3 451 p =, 1 831 2 3 4
- R:40,290 R:63,933 R:61,871 R:57,2631 0,41 794 0,040 0,2 190 592 0,41 794 0,132 195 13 0,04 0,132 195 0,5 936 144 0,219 059 1 0,593 614
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb abs. (fedenko-data)
- CDllb abs. Kruskal-Wallis test: H (3, N= 89) =24,10 601 p =, 1 2 3 4
- R:34,852 R:61,333 R:65,033 R:64,2941 0,8 749 0,145 0,13 962 0,8 749 0,7 716 13 0,145 0,7 716 0,11 454 0,1 396 1 0,1 145
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 (fedenko-data)
- CD50 Kruskal-Wallis test: H (3, N= 96) =6,616 044 p =, 8 521 2 3 4
- R:48,548 R:50,300 R:40,048 R:60,7891 1 1 0,7 890 052 1 1 13 1 1 0,636 244 0,789 005 1 0,63 624
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 abs. (fedenko-data)
- CD50 abs. Kruskal-Wallis test: H (3, N= 89) =25,20 469 p = 1 2 3 4
- R:36,481 R:55,200 R:34,033 R:68,8821 0,14 676 1 0,3 072 0,14 676 0,57 459 0,8 095 463 1 0,57 459 0,534 0,307 0,809 546 0,53
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA (fedenko-data)
- CD45RA Kruskal-Wallis test: H (3, N= 96) =2,953 944 p =, 39 881 2 3 4
- R:43,742 R:45,733 R:49,226 R:57,2631 1 1 0,574 362 1 1 13 1 1 14 0,57 436 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA abs. (fedenko-data)
- CD45RA abs. Kruskal-Wallis test: H (3, N= 89) =22,52 435 p =, 11 2 3 4
- R:36,778 R:53,267 R:35,067 R:68,2941 0,284 983 1 0,4 892 0,284 983 0,155 426 0,6 036 263 1 0,155 426 0,1 364 0,489 0,603 626 0,136
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 (fedenko-data)
- CD5 Kruskal-Wallis test: H (3, N= 96) =7,524 484 p = 5 691 2 3 4
- R: 50,43 5 R:37,100 R: 44,145 R:61,4471 0,767 997 1 12 0,767 997 1 0,683 433 1 1 0,1 981 474 1 0,68 343 0,198 147
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 abs. (fedenko-data)
- CD5 abs. Kruskal-Wallis test: H (3, N= 89) =25,76 310 p =, 1 2 3 4
- R:36,963 R:50,933 R:34,467 R:71,l 181 0,558 757 1 0,1 172 0,558 757 0,263 122 0,1 645 653 1 0,263 122 0,184 0,117 0,164 565 0,18
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 (fedenko-data)
- CD7 Kruskal-Wallis test: H (3, N= 96) =5,693 870 p =12 751 2 3 4
- R:45,387 R:46,700 R:44,177 R:62,0531 0 1 1 0,2 402 372 1 1 0,6 634 153 1 1 0,1 658 294 0,240 237 0,663 415 0,165 829
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 abs. (fedenko-data)
- CD7 abs. Kruskal-Wallis test: H (3, N= 89) =26,8 895 p =, 1 2 3 4
- R:35,778 R:53,600 R:34,700 R:70,2351 0,193 114 1 0,992 0,193 114 0,12 423 0,4 147 453 1 0,12 423 0,354 0,99 0,414 745 0,35
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 (fedenko-data)
- CD71 Kruskal-Wallis test: H (3, N= 95) =3,536 431 p =, 31 611 2 3 4
- R:49,717 R:36,800 R:52,661 R:46,5261 0,830 611 1 12 0,830 611 0,404 149 13 1 0,404 149 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 abs. (fedenko-data)
- CD71 abs. Kruskal-Wallis test: H (3, N= 88) =4,146 112 p = 24 611 2 3 4
- R:42,000 R:42,000 R:41,500 R:55,8241 1 1 0,4 966 542 1 1 0,7 598 883 1 1 0,3 885 814 0,496 654 0,759 888 0,388 581
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 (fedenko-data)
- CD95 Kruskal-Wallis test: H (3, N= 96) =14,46 357 p =, 231 2 3 4
- R:38,742 R:50,367 R:44,919 R:68,7891 1 1 0,12 832 1 1 0,333 163 1 1 0,196 294 0,1 283 0,33 316 0,19 629
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 abs. (fedenko-data)
- CD95 abs. Kruskal-Wallis test: H (3, N= 89) =28,37 237 p =, 1 2 3 4
- R:34,926 R:51,867 R:35,200 R:72,2351 0,250 412 1 0,192 0,250 412 0,248 122 0,1 562 793 1 0,248 122 0,144 0,19 0,156 279 0,14
- Depend.: Multiple Comparisons p values (2-tailed) — CD4/CD8 (fedenko-data)
- CD4/CD8 Kruskal-Wallis test: H (3, N= 96) =2,849 780 p =, 41 541 2 3 4
- R:49,371 R:46,933 R:53,565 R:40,0531 1 1 12 1 1 13 1 1 0,5 757 364 1 1 0,575 736
- Depend.: Multiple Comparisons p values (2-tailed) — IgG МЕ/мл (fedenko-data)
- G МЕ/мл Kruskal-Wallis test: H (3, N= 93) =13,7 084 p =, 451 2 3 4
- R:45,536 R:40,533 R:59,919 R:33,1841 1 0,245 702 0,7 419 262 1 0,134 368 13 0,245 702 0,134 368 0,40 484 0,741 926 1 0,4 048
- Depend.: Multiple Comparisons p values (2-tailed) — IgA МЕ/мл (fedenko-data)
- A МЕ/мл Kruskal-Wallis test: H (3, N= 93) =1,986 982 p = 57 511 2 3 4
- R:48,732 R:39,833 R:50,710 R:44,0531 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgM МЕ/мл (fedenko-data)
- M МЕ/мл Kruskal-Wallis test: H (3, N= 93) =1,734 641 p =, 62 931 2 3 4
- R:43,946 R:48,533 R:44,952 R:53,6321 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG г/л (fedenko-data)
- G г/л Kruskal-Wallis test: H (3, N= 93) =15,8 581 p =, 171 2 3 4
- R:45,000 R:39,800 R:61,097 R:32,6321 1 0,133 006 0,7 388 452 1 0,72 708 13 0,133 006 0,72 708 0,1 774 0,738 845 1 0,177
- Depend.: Multiple Comparisons p values (2-tailed) — IgA г/л (fedenko-data)
- A г/л Kruskal-Wallis test: H (3, N= 93) =2,254 901 p =, 52 121 2 3 4
- R:48,536 R:39,667 R:51,226 R:43,6321 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgM г/л (fedenko-data)
- M г/л Kruskal-Wallis test: H (3, N= 93) =1,734 641 p = 62 931 2 3 4
- R:43,946 R:48,533 R:44,952 R:53,6321 1 1 12 1 1 13 1 1 14 1 1 1
- Непараметрический критерий Краскела-Уоллиса.
- Статистический анализ проведен с помощью программы STATISTICA 6.0.1. ФАЗА 3
- Depend.: Multiple Comparisons р values (2-tailed) — лейкоц. (fedenko-data)лейкоц. Kruskal-Wallis test: H (3, N= 80) =3,786 879 p =, 2854 1 2 3 4
- R:36,364 R:45,800 R:36,630 R:47,7501 1 1 0,8 152 822 1 1 13 1 1 0,7 758 944 0,815 282 1 0,775 894
- Depend.: Multiple Comparisons p values (2-tailed) — лимф, (fedenko-data)лимф. Kruskal-Wallis test: H (3, N= 78) =6,955 953 p =, 0733 1 2 3 4
- R:35,167 R:48,433 R:33,154 R:47,1251 0,499 864 1 0,6 706 522 0,499 864 0,225 376 13 1 0,225 376 0,314 014 0,670 652 1 0,31 401
- Depend.: Multiple Comparisons p values (2-tailed) — лимф.абс. (fedenko-data)лимф.абс. Kruskal-Wallis test: H (3, N= 78) =16,30 703 p =, 0010 1 2 3 4
- R:28,833 R:51,300 R:33,l 15 R:52,8131 0,2 016 1 0,85 712 0,2 016 0,79 943 13 1 0,79 943 0,373 594 0,8 571 1 0,37 359
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 (fedenko-data)
- CD3 Kruskal-Wallis test: H (3, N= 91) =4,323 258 p =, 22 861 2 3 4
- R:44,583 R:41,633 R:43,306 R:58,7671 1 1 0,5 369 732 1 1 0,4 539 713 1 1 0,3 764 914 0,536 973 0,453 971 0,376 491
- Depend.: Multiple Comparisons p values (2-tailed) — CD3 abs. (fedenko-data)
- CD3 abs. Kruskal-Wallis test: H (3, N= 77) =14,69 183 p =, 211 2 3 4
- R:28,667 R:48,400 R:3 3,692 R:53,2671 0,54 457 1 0,6 862 0,54 457 0,255 605 13 1 0,255 605 0,417 894 0,686 1 0,41 789
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 (fedenko-data)
- CD4 Kruskal-Wallis test: H (3, N= 91) =5,588 435 p =, 13 341 2 3 4
- R:39,967 R:47,000 R:44,806 R:59,5331 1 1 0,1 149 082 1 1 13 1 1 0,4 576 744 0,114 908 1 0,457 674
- Depend.: Multiple Comparisons p values (2-tailed) — CD4 abs. (fedenko-data)
- CD4 abs. Kruskal-Wallis test: H (3, N= 77) =14,17 311 p =, 271 2 3 4
- R:27,810 R:48,667 R:44,846 R:52,2001 0,34 919 0,045 0,7 562 0,34 919 0,34 045 13 0,045 0,34 045 0,1 004 314 0,756 1 0,100 431
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 (fedenko-data)
- CD8 Kruskal-Wallis test: H (3, N= 91) = 7 892 973 p =, 85 201 2 3 4
- R:43,133 R:47,333 R:46,048 R:50,3001 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD8 abs. (fedenko-data)
- CD8 abs. Kruskal-Wallis test: H (3, N= 77) =12,8 320 p =, 711 2 3 4
- R:29,095 R:48,267 R:34,654 R:51,1331 0,67 493 1 0,214 162 0,67 493 0,363 385 13 1 0,363 385 0,1 385 694 0,21 416 1 0,138 569
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 (fedenko-data)
- CD20 Kruskal-Wallis test: H (3, N= 91) =10,71 747 p =, 1 341 2 3 4
- R:38,600 R:61,000 R:64,855 R:56,4331 0,43 938 0,038 0,196 542 0,43 938 0,91 875 13 0,038 0,91 875 0,3 645 864 0,19 654 1 0,364 586
- Depend.: Multiple Comparisons p values (2-tailed) — CD20 abs. (fedenko-data)
- CD20 abs. Kruskal-Wallis test: H (3, N= 77) =16,31 570 p =, 101 2 3 4
- R:29,571 R:53,133 R:31,846 R:50,4671 0,11 022 1 0,343 852 0,11 022 0,20 035 13 1 0,20 035 0,615 454 0,34 385 1 0,61 545
- Depend.: Multiple Comparisons p values (2-tailed) — HLA-DR (fedenko-data)
- HLA-DR Kruskal-Wallis test: H (3, N= 91) =1,907 244 p =, 59 191 2 3 4
- R:43,467 R:53,100 R:43,387 R:49,3671 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — HLADR abs. (fedenko- data)
- HLADR abs. Kruskal-Wallis test: H (3, N= 77) =12,71 515 p = 531 2 3 4
- R:30,619 R: 51,400 R:32,731 R:49,2001 0,3 601 1 0,841 082 0,3 601 0,60 363 13 1 0,60 363 0,1 390 824 0,84 108 1 0,139 082
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 (fedenko-data)
- CD38 Kruskal-Wallis test: H (3, N= 91) =10,68 116 p =, 1 361 2 3 4
- R:40,400 R:64,600 R:40,258 R:50,4671 0,22 584 1 12 0,22 584 0,20 333 0,8 568 983 1 0,20 333 14 1 0,856 898 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD38 abs. (fedenko-data)
- CD38 abs. Kruskal-Wallis test: H (3, N= 76) =20,94 017 p =, 11 2 3 4
- R:28,810 R:54,533 R:29,923 R:51,7861 0,3 417 1 0,153 942 0,3 417 0,3 528 13 1 0,3 528 0,169 324 0,15 394 1 0,16 932
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 (fedenko-data)
- CD25 Kruskal-Wallis test: H (3, N= 91) = 2 004 263 p = 97 751 2 3 4
- R:46,333 R:45,867 R:47,016 R:43,3671 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD25 abs. (fedenko-data)
- CD25 abs. Kruskal-Wallis test: H (3, N= 75) =1,555 640 p =, 66 951 2 3 4
- R:33,905 R:42,867 R:38,923 R:37,1541 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 (fedenko-data)
- CD16 Kruskal-Wallis test: H (3, N= 91) =3,158 826 p =, 36 781 2 3 4
- R:42,650 R:49,900 R:51,016 R:38,4331 1 1 12 1 1 13 1 1 0,7 792 284 1 1 0,779 228
- Depend.: Multiple Comparisons p values (2-tailed) — CD 16 abs. (fedenko-data)
- CD 16 abs. Kruskal-Wallis test: H (3, N= 77) =6,178 914 p =, 10 321 2 3 4
- R:29,857 R:57,667 R:59,231 R:42,7331 0,1 196 0,91 961 0,531 962 0,1 196 1 13 0,91 961 1 14 0,53 196 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb (fedenko-data)
- CDllb Kruskal-Wallis test: H (3, N= 91) =13,82 327 p =, 321 2 3 4
- R:36,817 R:62,533 R:40,984 R:58,2001 0,12 467 1 0,627 912 0,12 467 0,5 693 13 1 0,5 693 0,2 294 084 0,62 791 1 0,229 408
- Depend.: Multiple Comparisons p values (2-tailed) — CD1 lb abs. (fedenko- data)
- CDllb abs. Kruskal-Wallis test: H (3, N= 77) =21,60 139 p =, 11 2 3 4
- R:27,905 R:54,800 R:60,962 R:52,6671 0,2 258 0,001 0,63 612 0,2 258 0,6 089 13 0,001 0,6 089 0,166 154 0,6 361 1 0,16 615
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 (fedenko-data)
- CD50 Kruskal-Wallis test: H (3, N= 91) =, 1 324 082 p =, 98 771 2 3 4
- R:44,900 R:45,233 R:46,758 R:47,4001 1 1 12 1 1 13 1 1 14 I 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD50 abs. (fedenko-data)
- CD50 abs. Kruskal-Wallis test: H (3, N= 77) =15,48 981 p =, 141 2 3 4
- R:28,429 R:51,333 R:53,308 R:51,3331 0,14 746 0,011 0,147 462 0,14 746 0,77 728 13 0,011 0,77 728 0,777 284 0,14 746 1 0,77 728
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA (fedenko-data)
- CD45RA Kruskal-Wallis test: H (3, N= 91) =2,357 688 p =, 50 161 2 3 4
- R:42,050 R:42,033 R:48,242 R:53,2331 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — CD45RA abs. (fedenko- data)
- CD45RA abs. Kruskal-Wallis test: H (3, N= 77) =14,34 634 p =, 251 2 3 4
- R:28,429 R:48,667 R:44,077 R:52,6671 0,44 716 0,0481 0,81 092 0,44 716 0,265 736 13 0,0481 0,265 736 0,623 024 0,8 109 1 0,62 302
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 (fedenko-data)
- CD5 Kruskal-Wallis test: H (3, N= 91) =17,80 512 p =, 51 2 3 4
- R:45,350 R:47,800 R:34,435 R:69,4001 1 0,639 873 0,239 112 1 0,646 083 0,1 507 223 0,639 873 0,646 083 0,1 544 0,23 911 0,150 722 0,154
- Depend.: Multiple Comparisons p values (2-tailed) — CD5 abs. (fedenko-data)
- CD5 abs. Kruskal-Wallis test: H (3, N= 77) =19,7 004 p =, 31 2 3 4
- R:28,810 R:50,867 R:31,308 R: 54,7331 0,21 244 1 0,36 532 0,21 244 0,42 056 13 1 0,42 056 0,74 414 0,3 653 1 0,7 441
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 (fedenko-data)
- CD7 Kruskal-Wallis test: H (3, N= 91) =9,844 974 p = 1 991 2 3 4
- R:43,533 R:44,233 R:39,968 R:65,1671 1 1 0,575 862 1 1 0,1 798 473 1 1 0,145 174 0,57 586 0,179 847 0,14 517
- Depend.: Multiple Comparisons p values (2-tailed) — CD7 abs. (fedenko-data)
- CD7 abs. Kruskal-Wallis test: H (3, N= 77) =18,1 211 p =, 41 2 3 4
- R:28,143 R:49,733 R:32,500 R:54,7331 0,25 845 1 0,2 632 0,25 845 0,105 069 13 1 0,105 069 0,130 564 0,263 1 0,13 056
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 (fedenko-data)
- CD71 Kruskal-Wallis test: H (3, N= 91) =2,696 565 p = 44 081 2 3 4
- R:48,933 R:43,667 R:40,903 R:53,0001 1 1 12 1 1 13 1 1 0,8 721 794 1 1 0,872 179
- Depend.: Multiple Comparisons p values (2-tailed) — CD71 abs. (fedenko-data)
- CD71 abs. Kruskal-Wallis test: H (3, N= 77) =6,609 829 p =, 8 541 2 3 4
- R:33,952 R:44,067 R:33,962 R:49,7331 1 1 0,2 215 562 1 0,98 155 13 1 0,98 155 0,1 780 964 0,221 556 1 0,178 096
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 (fedenko-data)
- CD95 Kruskal-Wallis test: H (3, N= 91) =15,96 402 p =, 121 2 3 4
- R:38,000 R:48,100 R:41,242 R:69,7331 1 1 0,8 712 1 1 0,1 493 793 1 1 0,36 274 0,871 0,149 379 0,3 627
- Depend.: Multiple Comparisons p values (2-tailed) — CD95 abs. (fedenko-data)
- CD95 abs. Kruskal-Wallis test: H (3, N= 77) =20,76 252 p =, 11 2 3 4
- R:28,381 R:48,933 R:31,308 R:57,2671 0,3 947 1 0,8 032 0,3 947 0,90 625 13 1 0,90 625 0,20 724 0,803 1 0,2 072
- Depend.: Multiple Comparisons p values (2-tailed) — CD4/CD8 (fedenko-data)
- CD4/CD8 Kruskal-Wallis test: H (3, N= 91) =, 7 305 082 p =, 86 601 2 3 4
- R:45,350 R:45,600 R:44,306 R:51,2001 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG МЕ/мл (fedenko- data)
- G МЕ/мл Kruskal-Wallis test: H (3, N= 91) =8,329 339 p =, 3 971 2 3 4
- R:44,600 R:41,667 R:55,726 R:33,0331 1 0,600 202 0,9 966 982 1 0,543 511 13 0,600 202 0,543 511 0,378 254 0,996 698 1 0,37 825
- Depend.: Multiple Comparisons p values (2-tailed) — IgA МЕ/мл (fedenko- data)
- A МЕ/мл Kruskal-Wallis test: H (3, N= 91) =8,446 945 p =, 3 761 2 3 4
- R:43,900 R:30,767 R:54,452 R:47,9671 0,695 208 0,71 283 12 0,695 208 0,2 615 0,4 471 823 0,71 283 0,2 615 14 1 0,447 182 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgM МЕ/мл (fedenko- data)
- M МЕ/мл Kruskal-Wallis test: H (3, N= 91) =, 4 054 225 p =, 93 911 2 3 4
- R:46,017 R:46,933 R:44,016 R:49,1331 1 1 12 1 1 13 1 1 14 1 1 1
- Depend.: Multiple Comparisons p values (2-tailed) — IgG г/л (fedenko-data)
- G г/л Kruskal-Wallis test: H (3, N= 91) =9,834 156 p =, 2 001 2 3 4
- R:43,817 R:41,200 R:56,903 R:32,6331 1 0,31 828 12 1 0,352 371 13 0,31 828 0,352 371 0,209 084 1 1 0,20 908
- Depend.: Multiple Comparisons p values (2-tailed) — IgA г/л (fedenko-data)
- A г/л Kruskal-Wallis test: H (3, N= 91) =9,261 073 p =, 2 601 2 3 4
- R:43,450 R:30,500 R:55,194 R:47,6001 0,726 263 0,495 374 12 0,726 263 0,17 729 0,4 573 973 0,495 374 0,17 729 14 1 0,457 397 1
- Depend.: Multiple Comparisons р values (2-tailed) — IgM г/л (fedenko-data)
- M г/л Kruskal-Wallis test: H (3, N= 91) = 4 054 225 p = 93 911 2 3 4
- R:46,017 R:46,933 R:44,016 R:49,1331 1 1 12 1 1 13 1 1 14 1 1 11 234группа контроль группа ликопид группа полиоксидоний группа ликопид+полиоксидоний